Clinical features and prognostic analysis of mantle cell lymphoma / 中华血液学杂志
Chinese Journal of Hematology
;
(12): 814-818, 2012.
Article
in Chinese
| WPRIM
| ID: wpr-323485
ABSTRACT
<p><b>OBJECTIVE</b>To study the clinical features, therapeutic effects, survival time and prognostic factors of patents with mantle cell lymphoma (MCL).</p><p><b>METHODS</b>Clinical data of 47 MCL patients admitted from January 2002 to December 2011 were retrospectively analyzed.</p><p><b>RESULTS</b>Of all patients, median age was 58 year-old and male to female ratio was 3.31. Forty-two cases (89.4%) were in Ann Arbor stage III-IV, 13 cases (27.7%) with bone marrow involvement, 6 cases (12.8%) with lymphocytosis, 18 cases (38.3%) with elevated LDH, and 28 cases (59.6%) with elevated β(2)-MG. Age, bone marrow involvement, increased LDH level and treatment without rituximab were poor prognostic factors. The efficiency and complete remission rate of rituximab combined with chemotherapy were 91.4% and 48.6%, which were superior to those of CHOP regimen (41.7% and 16.7%). As compared to CHOP regimen, rituximab combined with chemotherapy induced longer progression-free survival and overall survival.</p><p><b>CONCLUSION</b>Most patients with MCL were older adults with a male predominance and usually had bone marrow involvement and poor prognosis. Rituximab combined with chemotherapy could significantly improve patient outcome.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Prognosis
/
Retrospective Studies
/
Lymphoma, Mantle-Cell
/
Therapeutic Uses
/
Diagnosis
/
Drug Therapy
/
Antibodies, Monoclonal, Murine-Derived
/
Rituximab
Type of study:
Diagnostic study
/
Observational study
/
Prognostic study
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
Language:
Chinese
Journal:
Chinese Journal of Hematology
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS